191 related articles for article (PubMed ID: 28480833)
21. Nano-Based Anti-Tubercular Drug Delivery and Therapeutic Interventions in Tuberculosis.
Sharma R; Kaur A; Sharma AK; Dilbaghi N; Sharma AK
Curr Drug Targets; 2017; 18(1):72-86. PubMed ID: 26240053
[TBL] [Abstract][Full Text] [Related]
22. Current nanotechnological strategies using lipids, carbohydrates, proteins and metal conjugates-based carrier systems for diagnosis and treatment of tuberculosis - A review.
Usharani N; Kanth SV; Saravanan N
Int J Biol Macromol; 2023 Feb; 227():262-272. PubMed ID: 36521715
[TBL] [Abstract][Full Text] [Related]
23. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
Mehanna MM; Mohyeldin SM; Elgindy NA
J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
[TBL] [Abstract][Full Text] [Related]
24. Quinoline: a promising antitubercular target.
Keri RS; Patil SA
Biomed Pharmacother; 2014 Oct; 68(8):1161-75. PubMed ID: 25458785
[TBL] [Abstract][Full Text] [Related]
25. The magic bullets and tuberculosis drug targets.
Zhang Y
Annu Rev Pharmacol Toxicol; 2005; 45():529-64. PubMed ID: 15822188
[TBL] [Abstract][Full Text] [Related]
26. Novel and Innovative Approach of Nanotechnology with their Applications in the Management of Infectious Disease, Tuberculosis: An Overview.
Singh S; Ahuja A
Recent Pat Nanotechnol; 2024; 18(2):140-163. PubMed ID: 35616678
[TBL] [Abstract][Full Text] [Related]
27. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery.
Miranda MS; Rodrigues MT; Domingues RMA; Torrado E; Reis RL; Pedrosa J; Gomes ME
Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():1090-1103. PubMed ID: 30274040
[TBL] [Abstract][Full Text] [Related]
28. Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis.
Rath G; Pradhan D; Ghosh G; Goyal AK
Curr Pharm Des; 2021; 27(17):2026-2040. PubMed ID: 33634753
[TBL] [Abstract][Full Text] [Related]
29. Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis--A Review.
da Silva PB; de Freitas ES; Bernegossi J; Gonçalez ML; Sato MR; Leite CQ; Pavan FR; Chorilli M
J Biomed Nanotechnol; 2016 Feb; 12(2):241-60. PubMed ID: 27305759
[TBL] [Abstract][Full Text] [Related]
30. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers.
Ganta S; Deshpande D; Korde A; Amiji M
Mol Membr Biol; 2010 Oct; 27(7):260-73. PubMed ID: 20929336
[TBL] [Abstract][Full Text] [Related]
31. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.
Xu Y; Wu J; Liao S; Sun Z
Ann Clin Microbiol Antimicrob; 2017 Oct; 16(1):67. PubMed ID: 28974222
[TBL] [Abstract][Full Text] [Related]
32. Tuberculosis chemotherapy: current drug delivery approaches.
du Toit LC; Pillay V; Danckwerts MP
Respir Res; 2006 Sep; 7(1):118. PubMed ID: 16984627
[TBL] [Abstract][Full Text] [Related]
33. Nanostructured drug delivery for better management of tuberculosis.
Kaur IP; Singh H
J Control Release; 2014 Jun; 184():36-50. PubMed ID: 24732260
[TBL] [Abstract][Full Text] [Related]
34. Liposomes as drug delivery systems for the treatment of TB.
Pinheiro M; Lúcio M; Lima JL; Reis S
Nanomedicine (Lond); 2011 Oct; 6(8):1413-28. PubMed ID: 22026379
[TBL] [Abstract][Full Text] [Related]
35. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.
Sosnik A; Carcaboso AM; Glisoni RJ; Moretton MA; Chiappetta DA
Adv Drug Deliv Rev; 2010 Mar; 62(4-5):547-59. PubMed ID: 19914315
[TBL] [Abstract][Full Text] [Related]
36. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
37. Mycobacterium tuberculosis treatment modalities and recent insights.
Sukhithasri V; Vinod V; Varma S; Biswas R
Curr Drug Deliv; 2014; 11(6):744-52. PubMed ID: 24947482
[TBL] [Abstract][Full Text] [Related]
38. Fighting tuberculosis: old drugs, new formulations.
Blasi P; Schoubben A; Giovagnoli S; Rossi C; Ricci M
Expert Opin Drug Deliv; 2009 Sep; 6(9):977-93. PubMed ID: 19678791
[TBL] [Abstract][Full Text] [Related]
39. Alginate-based sustained release drug delivery systems for tuberculosis.
Ahmad Z; Khuller GK
Expert Opin Drug Deliv; 2008 Dec; 5(12):1323-34. PubMed ID: 19040395
[TBL] [Abstract][Full Text] [Related]
40. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Vyas TK; Shahiwala A; Amiji MM
Int J Pharm; 2008 Jan; 347(1-2):93-101. PubMed ID: 17651927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
